Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more

Review Highlights Gaps in Publicly Funded Non-Inferiority Clinical Trials, Call for Better Design and Reporting Practices

Publicly funded non-inferiority trials have grown in popularity with high levels of non-inferiority margin reporting; however, a recent analysis notes a need for improved design and reporting practices to ensure clinical relevance and reliability.

Are GLP-1 Receptor Agonists Eliminating the Need for Bariatric Surgery?

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

Sam Altman Downplays the Dangers of AI and Musk

The chief executive of OpenAI said the technology would boost productivity and rejected worries that his rival mogul could use his political influence to harm competitors.

Cellino Appoints Chris Gemmiti, PhD, as SVP of Therapeutics Development

Cellino Biotech, Inc. closed biomanufacturing for personalized regenerative medicines, announced today the appointment of Chris Gemmiti, PhD, as Senior Vice President of Therapeutics Development. Dr. Gemmiti brings more than 25 years of experience in cell therapy and regenerative medicine, through both industry and academic roles, and extensive expertise as a leader in developing novel therapeutics.

Cancer Research Institute (CRI) on LinkedIn

"It's time for immunotherapy to really lean in and to start to embrace that data driven discovery, and CRI needs to play a role in that," emphasizes CRI's CEO, Alicia Zhou, PhD. Dive deeper into Dr. Zhou's vision for the future of the Cancer Research Institute, and understand how she aims to maximize the organization's impact, in a new interview with Pharmaceutical Executive: https://bit.ly/4gjBft7

#CancerResearch #Immunotherapy

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs